No abstract

The objective of writing this review on Floating Drug Delivery Systems (FDDS) was to accumulate new work with a special focus on the primary floatation mechanism for gastric retention. Drug delivery systems are those that instantly float on contact with gastric fluids and present promising approaches to improve the bioavailability of drugs with absorption windows in the stomach or upper small intestine, imbalanced in the intestinal or colonic environment, and exhibit low solubility at high pH standards. It is a novel drug delivery system that takes full advantage of effectiveness and compliance. Physical problems such as short gastric residence time and unpredictable gastric emptying time were overcome with the use of floating dosage forms that provide the possibility of local and systemic effects. The floating drug delivery system allows prolonged and continuous entry of the drug into the upper part of the gastric retention pathway and increases the bioavailability of the medication characterized by a narrow absorption window. This review provides detailed information on the pharmaceutical basis of its Introduction, Advantages, Disadvantages, Factors Affecting Gastric Emptying, and Criteria for Suitable Drug Products for Floating Gastric-Retention, Classification of Floating Multiparticulate Drug Delivery System, and Characterization of Floating Multiparticulate Drug Delivery System. These systems are beneficial for various difficulties encountered during the development of a pharmaceutical dosage form and the future potential of FDDS. This review article has attempted to announce to readers about the floating drug delivery system.

No abstract

No abstract

In the present study, dihydrobenzimidazole thiopyranooxazinone derivatives were efficiently synthesized, which were further characterized and authenticated by means of TLC and different spectral analysis such as IR and 1H NMR. The synthesized compounds DPK2d2 to DPK2d8 were screened for their in vitro antimicrobial, antitubercular and anticancer activities. The results showed that the titled compounds DPK3d1, DPK3d2 and DPK3d4 exhibited potent antimicrobial activity, shows a broadspectrum activity against Bacillus subtilis, Escherichia coli (antibacterial) and Aspergillus niger (antifungal) as compared to ciprofloxacin and fluconazole, respectively. Compounds DPK3d1, DPK3d3 and DPK3d5 exhibited potent antitubercular activities against Mycobacterium tuberculosis as compared to pyrazinamide, ciprofloxacin and streptomycin. Compounds DPK3d3, DPK3d4 and DPK3d5 showed highly potent cytotoxic activity against human lung cancer cell line (A549) as compared to adriamycin. In silico molecular docking studies shown that all the ligands highest binding affinity range -6.7 to -8.7 for selected 1CB4 PDB of superoxide dismutase, which recognized that ligands having antioxidant activity.